‘Middlemen’ Markups Are Penalizing Patients, Says AAM
Cash Prices For Generic Drugs Are Substantially Higher Than Manufacturer Prices
Executive Summary
The Association for Accessible Medicines has launched its Markup Madness campaign, which seeks to draw attention to the disparity in cost between generic drugs upon entry to the supply chain and when purchased in pharmacies.
You may also be interested in...
Biosimilars Forum Welcomes PBM Transparency Act
Senators Maria Cantwell and Chuck Grassley have introduced a bill which would limit pharmacy benefit managers’ ability to engage in “unfair and deceptive” business practices, a move which has been welcomed by the Biosimilars Forum.
Industry Hails Access Implications As FTC Promises PBM Probe
The US FTC’s announcement of an inquiry into PBMs will be music to the ears of the country’s generics and biosimilars industry, which has long called for action on abusive practices that undermine access.
Generics Industry Braces For New Wave Of Price Pressure
With pricing pressures already creeping up in recent years, 2022 is set to see the generics industry caught in the middle as prices are further squeezed while costs continue to rise. As major players prepare to announce their first-quarter financial results, In Vivo looks at views from industry leaders on how these pressures are affecting their businesses, and how they can be expected to play out.